Symbols / ABUS
ABUS Chart
About
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 857.77M |
| Enterprise Value | 755.21M | Income | -42.28M | Sales | 14.61M |
| Book/sh | 0.40 | Cash/sh | 0.49 | Dividend Yield | — |
| Payout | 0.00% | Employees | 44 | IPO | — |
| P/E | — | Forward P/E | -26.53 | PEG | — |
| P/S | 58.73 | P/B | 11.07 | P/C | — |
| EV/EBITDA | -24.62 | EV/Sales | 51.70 | Quick Ratio | 18.31 |
| Current Ratio | 18.80 | Debt/Eq | 5.95 | LT Debt/Eq | — |
| EPS (ttm) | -0.23 | EPS next Y | -0.17 | EPS Growth | — |
| Revenue Growth | -60.50% | Earnings | 2026-03-26 | ROA | -16.46% |
| ROE | -45.88% | ROIC | — | Gross Margin | -98.86% |
| Oper. Margin | -15.68% | Profit Margin | -289.45% | Shs Outstand | 192.32M |
| Shs Float | 124.53M | Short Float | 10.00% | Short Ratio | 8.95 |
| Short Interest | — | 52W High | 5.10 | 52W Low | 2.71 |
| Beta | 0.72 | Avg Volume | 1.56M | Volume | 1.22M |
| Target Price | $5.74 | Recom | None | Prev Close | $4.39 |
| Price | $4.46 | Change | 1.59% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.74
Mean price target
2. Current target
$4.46
Latest analyst target
3. DCF / Fair value
$-2.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.46
Low
$5.06
High
$7.04
Mean
$5.74
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-14 | main | Chardan Capital | Buy → Buy | $5 |
| 2025-08-11 | main | Chardan Capital | Buy → Buy | $5 |
| 2025-03-28 | main | Chardan Capital | Buy → Buy | $5 |
| 2025-01-21 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-20 | main | Chardan Capital | Buy → Buy | $5 |
| 2024-11-18 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-07 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-07 | main | Chardan Capital | Buy → Buy | $5 |
| 2024-09-05 | main | Jefferies | Buy → Buy | $7 |
| 2024-08-02 | main | JMP Securities | Market Outperform → Market Outperform | $5 |
| 2024-06-07 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-06 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-05 | main | Chardan Capital | Buy → Buy | $4 |
| 2024-05-03 | reit | Chardan Capital | Buy → Buy | $4 |
| 2024-04-04 | reit | JMP Securities | Market Outperform → Market Outperform | $4 |
| 2024-03-01 | reit | Chardan Capital | Buy → Buy | $4 |
| 2024-03-01 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-08-04 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-08-04 | reit | Chardan Capital | Buy → Buy | $6 |
- Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 01 Sep 2025 07
- Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.8% - What's Next? - MarketBeat Mon, 02 Feb 2026 08
- Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts (NASDAQ:ABUS) - Seeking Alpha ue, 03 Feb 2026 08
- Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Intellectia AI hu, 19 Feb 2026 19
- ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? - Stocktwits Fri, 16 Jan 2026 08
- Arbutus Biopharma CEO Discusses Lawsuits Over LNP Technology - TipRanks hu, 11 Dec 2025 08
- ABUS Stock Tumbles on European Patent Revocation - StocksToTrade Sat, 17 Jan 2026 08
- Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire hu, 13 Nov 2025 08
- Moderna dealt blows in ongoing patent dispute with Arbutus - Seeking Alpha Wed, 18 Feb 2026 14
- Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Mon, 12 Jan 2026 08
- Arbutus Biopharma Shares Fall 19% On European Patent Revocation - Nasdaq Fri, 16 Jan 2026 08
- Arbutus Biopharma Stock Plummets After Key Patent Revocation - timothysykes.com Sat, 17 Jan 2026 08
- Arbutus Biopharma (ABUS) Shares Surge Amid Market Fluctuations - GuruFocus Mon, 02 Feb 2026 08
- Arbutus Biopharma’s Patent Ruling in Pfizer Lawsuit - TipRanks Wed, 10 Sep 2025 07
- Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance Wed, 06 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 28000 | — | — | Stock Award(Grant) at price 0.00 per share. | ANDROSKI LINDSAY J.D. | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 73500 | — | — | Stock Award(Grant) at price 0.00 per share. | NGUYEN TUAN | Chief Financial Officer | — | 2026-02-02 00:00:00 | D |
| 2 | 54300 | — | — | Stock Award(Grant) at price 0.00 per share. | NAFTZGER J CHRISTOPHER | General Counsel | — | 2025-02-14 00:00:00 | D |
| 3 | 90100 | — | — | Stock Award(Grant) at price 0.00 per share. | HASTINGS DAVID C | Chief Financial Officer | — | 2025-02-14 00:00:00 | D |
| 4 | 49300 | — | — | Stock Award(Grant) at price 0.00 per share. | SIMS KAREN | Officer | — | 2025-02-14 00:00:00 | D |
| 5 | 11333 | 37206 | — | Sale at price 3.28 per share. | NAFTZGER J CHRISTOPHER | General Counsel | — | 2025-02-04 00:00:00 | D |
| 6 | 22183 | 72827 | — | Sale at price 3.28 per share. | HASTINGS DAVID C | Chief Financial Officer | — | 2025-02-04 00:00:00 | D |
| 7 | 19348 | 63519 | — | Sale at price 3.28 per share. | SIMS KAREN | Officer | — | 2025-02-04 00:00:00 | D |
| 8 | 8846 | 32637 | — | Sale at price 3.69 per share. | MANCHESTER KEITH S | Director | — | 2024-08-14 00:00:00 | D |
| 9 | 54915 | 30752 | — | Conversion of Exercise of derivative security at price 0.56 per share. | MANCHESTER KEITH S | Director | — | 2024-08-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -473.55K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -62.01M | -70.94M | -59.60M | -69.77M |
| TotalUnusualItems | -6.39M | -44.00K | -2.25M | -1.87M |
| TotalUnusualItemsExcludingGoodwill | -6.39M | -44.00K | -2.25M | -1.87M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -69.92M | -72.85M | -69.46M | -76.25M |
| ReconciledDepreciation | 1.38M | 1.40M | 1.43M | 1.75M |
| EBITDA | -68.40M | -70.99M | -61.86M | -71.64M |
| EBIT | -69.78M | -72.39M | -63.29M | -73.39M |
| NetInterestIncome | 6.45M | 5.23M | 466.00K | -2.73M |
| InterestExpense | 137.00K | 459.00K | 1.73M | 2.86M |
| InterestIncome | 6.58M | 5.69M | 2.19M | 127.00K |
| NormalizedIncome | -63.53M | -72.81M | -67.67M | -74.38M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -69.92M | -72.85M | -69.46M | -76.25M |
| TotalExpenses | 76.14M | 96.17M | 102.24M | 82.64M |
| TotalOperatingIncomeAsReported | -76.32M | -78.10M | -65.46M | -73.52M |
| DilutedAverageShares | 185.61M | 165.96M | 150.94M | 106.24M |
| BasicAverageShares | 185.61M | 165.96M | 150.94M | 106.24M |
| DilutedEPS | -0.38 | -0.44 | -0.46 | -0.83 |
| BasicEPS | -0.38 | -0.44 | -0.46 | -0.83 |
| DilutedNIAvailtoComStockholders | -69.92M | -72.85M | -69.46M | -88.39M |
| NetIncomeCommonStockholders | -69.92M | -72.85M | -69.46M | -88.39M |
| OtherunderPreferredStockDividend | 0.00 | 12.14M | ||
| NetIncome | -69.92M | -72.85M | -69.46M | -76.25M |
| NetIncomeIncludingNoncontrollingInterests | -69.92M | -72.85M | -69.46M | -76.25M |
| NetIncomeContinuousOperations | -69.92M | -72.85M | -69.46M | -76.25M |
| TaxProvision | 0.00 | 0.00 | 4.44M | 0.00 |
| PretaxIncome | -69.92M | -72.85M | -65.01M | -76.25M |
| OtherIncomeExpense | -6.39M | -44.00K | -2.25M | -1.87M |
| SpecialIncomeCharges | -6.34M | -69.00K | -2.23M | -1.87M |
| RestructuringAndMergernAcquisition | 6.34M | 69.00K | 2.23M | 1.87M |
| EarningsFromEquityInterest | 0.00 | |||
| GainOnSaleOfSecurity | -49.00K | 25.00K | -22.00K | 5.00K |
| NetNonOperatingInterestIncomeExpense | 6.45M | 5.23M | 466.00K | -2.73M |
| InterestExpenseNonOperating | 137.00K | 459.00K | 1.73M | 2.86M |
| InterestIncomeNonOperating | 6.58M | 5.69M | 2.19M | 127.00K |
| OperatingIncome | -69.97M | -78.03M | -63.22M | -71.65M |
| OperatingExpense | 76.14M | 96.17M | 102.24M | 82.64M |
| ResearchAndDevelopment | 54.04M | 73.70M | 84.41M | 65.50M |
| SellingGeneralAndAdministration | 22.11M | 22.48M | 17.83M | 17.14M |
| GeneralAndAdministrativeExpense | 22.11M | 22.48M | 17.83M | 17.14M |
| OtherGandA | 22.11M | 22.48M | 17.83M | 17.14M |
| TotalRevenue | 6.17M | 18.14M | 39.02M | 10.99M |
| OperatingRevenue | 6.17M | 18.14M | 39.02M | 10.99M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 189.96M | 169.87M | 157.46M | 144.99M |
| ShareIssued | 189.96M | 169.87M | 157.46M | 144.99M |
| TotalDebt | 1.29M | 1.77M | 2.19M | 2.61M |
| TangibleBookValue | 97.37M | 106.02M | 136.85M | 169.44M |
| InvestedCapital | 97.37M | 106.02M | 136.85M | 169.44M |
| WorkingCapital | 111.70M | 109.54M | 118.28M | 149.44M |
| NetTangibleAssets | 97.37M | 106.02M | 136.85M | 169.44M |
| CapitalLeaseObligations | 1.29M | 1.77M | 2.19M | 2.61M |
| CommonStockEquity | 97.37M | 106.02M | 136.85M | 169.44M |
| TotalCapitalization | 97.37M | 106.02M | 136.85M | 169.44M |
| TotalEquityGrossMinorityInterest | 97.37M | 106.02M | 136.85M | 169.44M |
| StockholdersEquity | 97.37M | 106.02M | 136.85M | 169.44M |
| GainsLossesNotAffectingRetainedEarnings | -48.13M | -48.42M | -50.49M | -48.34M |
| OtherEquityAdjustments | -48.13M | -48.42M | -50.49M | -48.34M |
| RetainedEarnings | -1.35B | -1.28B | -1.20B | -1.13B |
| AdditionalPaidInCapital | 82.05M | 81.27M | 72.41M | 65.48M |
| CapitalStock | 1.41B | 1.35B | 1.32B | 1.29B |
| CommonStock | 1.41B | 1.35B | 1.32B | 1.29B |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 34.34M | 38.38M | 58.57M | 35.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 18.72M | 15.90M | 25.71M | 23.82M |
| OtherNonCurrentLiabilities | 15.05M | 14.55M | 17.90M | 21.59M |
| NonCurrentDeferredLiabilities | 2.86M | 0.00 | 6.00M | 0.00 |
| NonCurrentDeferredRevenue | 2.86M | 0.00 | 6.00M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 806.00K | 1.34M | 1.81M | 2.23M |
| LongTermCapitalLeaseObligation | 806.00K | 1.34M | 1.81M | 2.23M |
| CurrentLiabilities | 15.62M | 22.49M | 32.86M | 11.22M |
| OtherCurrentLiabilities | 26.00K | |||
| CurrentDeferredLiabilities | 7.57M | 11.79M | 16.46M | 0.00 |
| CurrentDeferredRevenue | 7.57M | 11.79M | 16.46M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 483.00K | 425.00K | 372.00K | 383.00K |
| CurrentCapitalLeaseObligation | 483.00K | 425.00K | 372.00K | 383.00K |
| PayablesAndAccruedExpenses | 7.56M | 10.27M | 16.03M | 10.84M |
| CurrentAccruedExpenses | 5.25M | 7.05M | 12.51M | 7.66M |
| Payables | 2.32M | 3.22M | 3.52M | 3.17M |
| AccountsPayable | 2.32M | 3.22M | 3.52M | 3.17M |
| TotalAssets | 131.71M | 144.40M | 195.42M | 204.49M |
| TotalNonCurrentAssets | 4.39M | 12.37M | 44.28M | 43.82M |
| OtherNonCurrentAssets | 34.00K | 103.00K | 61.00K | |
| InvestmentsAndAdvances | 0.00 | 6.28M | 37.36M | 35.69M |
| InvestmentinFinancialAssets | 0.00 | 6.28M | 37.36M | 35.69M |
| HeldToMaturitySecurities | 0.00 | 6.28M | 37.36M | |
| AvailableForSaleSecurities | 37.36M | 35.69M | ||
| NetPPE | 4.36M | 6.09M | 6.81M | 8.07M |
| AccumulatedDepreciation | -13.00M | -11.90M | -10.80M | -9.37M |
| GrossPPE | 17.35M | 17.99M | 17.61M | 17.45M |
| Leases | 8.59M | 8.59M | 8.59M | 8.56M |
| OtherProperties | 8.29M | 9.01M | 8.63M | 8.50M |
| MachineryFurnitureEquipment | 477.00K | 391.00K | 391.00K | 386.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 127.32M | 132.03M | 151.14M | 160.66M |
| OtherCurrentAssets | 2.28M | 4.25M | 2.87M | 4.45M |
| PrepaidAssets | 4.45M | |||
| Receivables | 2.41M | 1.78M | 1.35M | 899.00K |
| AccountsReceivable | 2.41M | 1.78M | 1.35M | 899.00K |
| CashCashEquivalentsAndShortTermInvestments | 122.62M | 126.00M | 146.91M | 155.32M |
| OtherShortTermInvestments | 86.29M | 99.72M | 116.14M | 46.03M |
| CashAndCashEquivalents | 36.33M | 26.29M | 30.78M | 109.28M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -65.03M | -86.94M | -35.87M | -68.34M |
| IssuanceOfCapitalStock | 44.12M | 29.85M | 20.32M | 134.66M |
| CapitalExpenditure | -182.00K | -1.01M | -512.00K | -809.00K |
| EndCashPosition | 36.33M | 26.29M | 30.78M | 109.28M |
| BeginningCashPosition | 26.29M | 30.78M | 109.28M | 52.25M |
| EffectOfExchangeRateChanges | -49.00K | 25.00K | -22.00K | 5.00K |
| ChangesInCash | 10.09M | -4.52M | -78.48M | 57.03M |
| FinancingCashFlow | 52.00M | 30.65M | 31.81M | 137.24M |
| CashFlowFromContinuingFinancingActivities | 52.00M | 30.65M | 31.81M | 137.24M |
| ProceedsFromStockOptionExercised | 7.87M | 795.00K | 11.49M | 2.57M |
| NetCommonStockIssuance | 44.12M | 29.85M | 20.32M | 134.66M |
| CommonStockIssuance | 44.12M | 29.85M | 20.32M | 134.66M |
| InvestingCashFlow | 22.95M | 50.77M | -74.94M | -12.68M |
| CashFlowFromContinuingInvestingActivities | 22.95M | 50.77M | -74.94M | -12.68M |
| NetInvestmentPurchaseAndSale | 23.13M | 51.76M | -74.43M | -11.87M |
| SaleOfInvestment | 164.64M | 132.27M | 56.00M | 70.35M |
| PurchaseOfInvestment | -141.51M | -80.51M | -130.43M | -82.22M |
| NetPPEPurchaseAndSale | -182.00K | -988.00K | -512.00K | -809.00K |
| SaleOfPPE | 0.00 | 20.00K | 0.00 | |
| PurchaseOfPPE | -182.00K | -1.01M | -512.00K | -809.00K |
| OperatingCashFlow | -64.85M | -85.94M | -35.36M | -67.53M |
| CashFlowFromContinuingOperatingActivities | -64.85M | -85.94M | -35.36M | -67.53M |
| ChangeInWorkingCapital | -2.83M | -18.23M | 29.24M | 925.00K |
| ChangeInOtherWorkingCapital | -1.36M | -10.66M | 22.45M | |
| ChangeInOtherCurrentLiabilities | -430.00K | -444.00K | -405.00K | -374.00K |
| ChangeInPayablesAndAccruedExpense | -2.71M | -5.76M | 5.22M | 1.91M |
| ChangeInPayable | 5.22M | 1.91M | ||
| ChangeInAccountPayable | 5.22M | 1.91M | ||
| ChangeInPrepaidAssets | 2.30M | -943.00K | 2.43M | -1.02M |
| ChangeInReceivables | -633.00K | -424.00K | -453.00K | 413.00K |
| ChangesInAccountReceivables | -633.00K | -424.00K | -453.00K | 413.00K |
| OtherNonCashItems | 501.00K | -3.34M | -3.70M | -1.39M |
| StockBasedCompensation | 8.99M | 9.30M | 7.18M | 6.42M |
| AssetImpairmentCharge | 167.00K | 0.00 | ||
| AmortizationOfSecurities | -3.13M | -2.20M | -54.00K | 999.00K |
| DepreciationAmortizationDepletion | 1.38M | 1.40M | 1.43M | 1.75M |
| DepreciationAndAmortization | 1.38M | 1.40M | 1.43M | 1.75M |
| Depreciation | 1.38M | 1.40M | 1.43M | 1.75M |
| OperatingGainsLosses | -20.00K | -5.00K | ||
| NetForeignCurrencyExchangeGainLoss | -5.00K | |||
| GainLossOnSaleOfPPE | 0.00 | -20.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -69.92M | -72.85M | -69.46M | -76.25M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ABUS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|